Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
aplastic anemia
MeSH D000741 - aplastic anemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D000080983:
Bone marrow failure disorders
0 Companies
0 Drugs
Success rate
D000740:
Anemia
24 Companies
15 Drugs
$
Success rate
D000741:
Aplastic anemia
4 Companies
3 Drugs
$
Success rate
D029502:
Hypoplastic anemia congenital
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Novartis
Eltrombopag olamine
Promacta
2022-11-20
2008-11-20
$2,163 M
Q2/22-Q2/25
Eltrombopag
Revolade
2010-03-11
Clinical Trials
Historical Success Rate
Phase 1
94
%
32/34
Phase 2
33
%
19/58
Phase 3
28
%
5/18
Approved:
2
Overall Success rate:
9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Novartis
Eltrombopag
,
Eltrombopag olamine
,
Iron dextran
,
Bevifimod
,
Globulin, immune
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use